Pershing Edward bought PVCT
March 20, 2026 · Form 4 insider transaction
Pershing Edward bought 49,067 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
49,067
Price
$0.00
Total value
N/A
InsiderPershing Edward
Role—
SecuritySeries D-1 Convertible Preferred Stock
Transaction codeM: Option exercise
Transaction dateMarch 20, 2026
Filing dateMarch 20, 2026
Shares owned after2,710,054
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.